机构：[1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China[3]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China[4]Tongji Hospital Tongji Medical College of Huazhong University of Science &Technology, Wuhan, Hubei, China华中科技大学同济医学院附属同济医院[5]Department of Hematology, First Hospital of Jilin University, Changchun, Jilin, China[6]Qilu Hospital of Shandong University, Jinan, Shandong, China[7]Wilis F. Pierce Memorial Hospital, Fuzhou, Fujian, China中山大学附属第二医院[8]Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China[9]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[10]Henan Cancer Hospital, Zhengzhou, Henan, China河南省肿瘤医院[11]Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Hematologic Disease Institute, Urumgi, Xinjiang, China[12]The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China[13]Department of Hematology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China[14]Affiliated Hospital of Hebei University, Baoding, Hebei, China河北大学附属医院[15]Anshan Central Hospital, Anshan, Liaoning, China[16]The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang, China[17]The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China[18]Xiehe Hospital Tongji Medical College of Huazhong University of Science &Technology, Wuhan, Hubei, China[19]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China四川大学华西医院
To evaluate the efficacy and safety of flumatinib in the later-line treatment of Chinese patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CP-CML previously treated with tyrosine kinase inhibitors (TKIs). Patients with CML-CP were evaluated for the probabilities of responses including complete hematologic response (CHR), cytogenetic response, and molecular response (MR) and adverse events (AEs) after the later-line flumatinib therapy. Of 336 enrolled patients with median age 50 years, median duration of treatment with flumatinib was 11.04 (2-25.23) months. Patients who achieved clinical responses at baseline showed maintenance of CHR, complete cytogenetic response (CCyR)/2-log molecular response (MR2), major molecular response (MMR), and 4-log molecular response or deep molecular response (MR4/DMR) in 100%, 98.9%, 98.6%, and 92.9% patients, respectively. CHR, CCyR/MR2, MMR, and MR4/DMR responses were achieved in 86.4%, 52.7%, 49.6%, and 23.5% patients respectively, which showed the lack of respective clinical responses at baseline. The patients without response at baseline, treated with flumatinib as 2L TKI, having no resistance to prior TKI or only resistance to imatinib, with response to last TKI, and with BCR::ABL ≤10% had higher CCyR/MR2, MMR, or MR4/DMR. The AEs observed during the later-line flumatinib treatment were tolerable and consistent with those reported with the first-line therapy. Flumatinib was effective and safe in patients who are resistant or intolerant to other TKIs. In particular, 2L flumatinib treatment induced high response rates and was more beneficial to patients without previous 2G TKI resistance, thus serving as a probable treatment option for these patients.
基金：
The work was supported by Science and Technology Project of Tianjin (grant no.
21JCQNJC01540). The authors would like to thank all doctors participating in this study.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|1 区医学
小类|2 区血液学
第一作者：
第一作者机构：[1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yang Yunfan,Liu Yuntao,Sun Hui,et al.Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia[J].Haematologica.2024,doi:10.3324/haematol.2023.284892.
APA：
Yang Yunfan,Liu Yuntao,Sun Hui,Meng Li,Lin Hai...&Wang Jianxiang.(2024).Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia.Haematologica,,
MLA：
Yang Yunfan,et al."Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia".Haematologica .(2024)
医学